Payment overview · 2025
General Payments
$1,816.31
117 reported records · 23 companies
Healthcare provider profile · identity verified
William C Holvik, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VISALIA, CA · NPI 1346225364
Verified facts
What the public records show
CMS Open Payments records show William C Holvik, M.D. received $1,816.31 in general payments during 2025 across 117 reported records.
Lilly USA, LLC accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Sunosi, Trelegy Ellipta, Veozah, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xyosted by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Auvelity by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Sunosi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $281.90 | 15.5% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $196.83 | 10.8% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $192.80 | 10.6% | 28 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.33 | 9.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.17 | 8.5% | 5 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.39 | 6.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $110.17 | 6.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.92 | 5.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.89 | 3.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.46 | 3.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.27 | 2.6% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $46.01 | 2.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $40.99 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.29 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.21 | 1.5% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $25.89 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.55 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.91 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.85 | 1.3% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $20.75 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.52 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.16 | 0.8% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,816.31 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $201.12 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $155.05 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.08 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $129.08 | 8 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $121.88 | 9 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $116.39 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.67 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $110.17 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.00 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $74.95 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $66.14 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $63.46 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.93 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.93 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.27 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $46.01 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.90 | 19 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.21 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $9.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $4.67 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 168 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 206 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
206 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 854 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 483 | 147 |
| Losartan Potassium | Losartan Potassium | 451 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 119 |
| Montelukast Sodium | Montelukast Sodium | 389 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 105 |
| Lisinopril | Lisinopril | 315 | 103 |
| Omeprazole | Omeprazole | 309 | 97 |
| Sertraline Hcl | Sertraline Hcl | 291 | 72 |
| Gabapentin | Gabapentin | 287 | 81 |
| Famotidine | Famotidine | 278 | 89 |
| Carvedilol | Carvedilol | 272 | 80 |
| Alprazolam | Alprazolam | 268 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 78 |
| Trazodone Hcl | Trazodone Hcl | 242 | 55 |
| Metformin Hcl | Metformin Hcl | 230 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 64 |
| Ozempic | Semaglutide | 206 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 204 | 60 |
| Furosemide | Furosemide | 189 | 72 |
| Eliquis | Apixaban | 168 | 45 |
| Modafinil | Modafinil | 165 | 49 |
| Ezetimibe | Ezetimibe | 164 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 55 |
| Irbesartan | Irbesartan | 148 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 47 |
| Allopurinol | Allopurinol | 115 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 23 |
| Potassium Chloride | Potassium Chloride | 104 | 39 |
| Atenolol | Atenolol | 103 | 30 |
| Azithromycin | Azithromycin | 103 | 51 |
| Clonazepam | Clonazepam | 101 | 17 |
| Methylprednisolone | Methylprednisolone | 96 | 82 |
| Estradiol | Estradiol | 93 | 28 |
| Spironolactone | Spironolactone | 93 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 25 |
| Jardiance | Empagliflozin | 90 | 28 |
| Metformin Hcl Er | Metformin Hcl | 90 | 31 |
| Tramadol Hcl | Tramadol Hcl | 87 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 25 |
| Bupropion Xl | Bupropion Hcl | 85 | 28 |
| Lorazepam | Lorazepam | 85 | 16 |
| Prednisone | Prednisone | 82 | 50 |
| Glimepiride | Glimepiride | 81 | 24 |
| Alendronate Sodium | Alendronate Sodium | 78 | 26 |
| Valsartan | Valsartan | 78 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 13 |
| Januvia | Sitagliptin Phosphate | 72 | 18 |
| Celecoxib | Celecoxib | 71 | 19 |
| Simvastatin | Simvastatin | 69 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 23 |
| Azelastine Hcl | Azelastine Hcl | 57 | 23 |
| Farxiga | Dapagliflozin Propanediol | 56 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 18 |
| Fenofibrate | Fenofibrate | 54 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 51 | 15 |
| Naproxen | Naproxen | 51 | 20 |
| Levetiracetam | Levetiracetam | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 17 |
| Bupropion Hcl | Bupropion Hcl | 49 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 29 |
| Digoxin | Digoxin | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Fluconazole | Fluconazole | 42 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 14 |
| Doxepin Hcl | Doxepin Hcl | 41 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 34 |
| Cephalexin | Cephalexin | 37 | 29 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Meloxicam | Meloxicam | 35 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Progesterone | Progesterone, Micronized | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 11 |
| Amiloride Hcl | Amiloride Hcl | 27 | 11 |
| Diazepam | Diazepam | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 13 |
| Belsomra | Suvorexant | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Xyosted | Testosterone Enanthate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Primidone | Primidone | 18 | suppressed |
| Sunosi | Solriamfetol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,816.31 · 117 records | Lilly USA, LLC | ACCRUFER, AFREZZA, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, CREON, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, ISTURISA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Nalu Neurostimulation System, Ozempic, PAXLOVID, QULIPTA, RECORLEV, REXULTI, Repatha, Rybelsus, Sunosi, TRELEGY ELLIPTA, Tlando, UBRELVY, VAXNEUVANCE, VOQUEZNA, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error